Successful use of azithromycin for Escherichia coli–associated renal allograft malakoplakia: a report of two cases

Case report: A rare case of malacoplakia resembling a malignant tumor of the cervix: a case report and review of the literature

“…We also administered a special vaginal lavage after surgery. The optimal duration of antibiotic therapy for patients with malacoplakia is unclear, and typically ranges from 12 weeks to 6 months ( 14 ). We chose to administer the drug vaginally for 3 months continuously, and the patient did not relapse within 12 months after surgery.…”

“…At present, the treatment and prognosis of malacoplakia patients with uterine preservation are unclear. The cases and treatments reported below provide new ideas for the clinical treatment of genital tract malacoplakia ( 14 ).…”

Decoding the enigma: unveiling the molecular transmission of avian-associated tet(X4)-positive E. coli in Sichuan Province, China

“…However, the widespread use of CHL analogs has led to the prevalent presence of CHL related ARGs ( Yang et al, 2022 ). In addition, AZM is a common antibiotic drug in clinical practice, although azithromycin breakpoint for E. coli is not covered in CLSI and EUCAST, and there are clear reports for its resistance breakpoint (32 mg/L) ( Gomes et al, 2019 ; Kinsella et al, 2021 ). With the continuous spread and prevalence of tet (X4)-positive E. coli , the treatment of MDR bacteria faces greater challenges.…”

“…The following antibiotics were used in bacterial sensitivity tests: tigecycline ( TGC ), azithromycin ( AZM ), gatifloxacin ( GAT ), piperacillin ( PRL ), ceftazidime ( CAZ ), kanamycin sulfate ( KAN ), imipenem ( IPM ), chloramphenicol ( CHL ), and trimethoprim ( TMP ). The above antibiotics were obtained from Dalian Meilun Biotechnology Co., Ltd. or Shanghai Maclean Biochemical Technology Co., Ltd. Antimicrobial resistance breakpoints are based on CLSI criteria, except for TGC which is based on the European Committee on Antimicrobial Susceptibility Testing ( EUCAST ) ( http://www.eucast.org ) ( Table S2 ) and AZM breakpoints (MIC = 32 mg/L) which is based on recommendations from recent studies ( Gomes et al, 2019 ; Kinsella et al, 2021 ). Specifically, 100 μL of bacterial solution and 100 μL of different concentrations of antibiotics were added to a 96-well microtiter plate at a final concentration of 0.25 to 512 mg/L, and the bacterial solution concentration was approximately 10 6 CFU/mL.…”